Scientists
Patients
Medical Professionals
Investors & Media
Careers
About
Leadership
History
Collaborations
Industrial Operations
Locations
Science
Pipeline
Research Areas
Technology
Regeneron Genetics Center
Scientific Publications
Medicines
ARCALYST® (rilonacept) INJECTION
DUPIXENT® (dupilumab) INJECTION
EYLEA® (aflibercept) INJECTION
KEVZARA® (sarilumab) INJECTION
LIBTAYO® (cemiplimab-rwlc) INJECTION
PRALUENT® (alirocumab) INJECTION
Citizenship
Science Education
Science Talent Search
Sustainable Communities
Supporting Patients
Culture of Integrity
Grants
Investors & Media
News
 Events & Presentations
Stock Information
Financial Information
Corporate Governance
FAQs
Careers
Scientists
Patients
Medical Professionals
Contact Us
Regeneron (NASDAQ: REGN) is a leading science and technology company delivering life-transforming medicines for serious diseases.
Read on
Our robust research and development engine allows us to discover therapies that could have a profound impact on patient health.
Read on
Our goal is to address serious medical conditions, across multiple and diverse therapeutic areas. Our FDA-approved medicines are only the beginning of our long-term commitment to solve the human body's most complex mysteries.
Read on
In addition to our work to invent new and needed medicines, we are focused on improving our world and operating with the highest standards of integrity. This commitment underscores our philosophy of “doing well by doing good,” every day.
Read on
About
Leadership
History
Collaborations
Industrial Operations
Locations
Science
Pipeline
Research Areas
Technology
Regeneron Genetics Center
Scientific Publications
Medicines
ARCALYST® (rilonacept) INJECTION
DUPIXENT® (dupilumab) INJECTION
EYLEA® (aflibercept) INJECTION
KEVZARA® (sarilumab) INJECTION
LIBTAYO® (cemiplimab-rwlc) INJECTION
PRALUENT® (alirocumab) INJECTION
Citizenship
Science Education
Science Talent Search
Sustainable Communities
Supporting Patients
Culture of Integrity
Grants
Investors & Media
News
 Events & Presentations
Stock Information
Financial Information
Corporate Governance
FAQs
Careers
Scientists
Patients
Medical Professionals
Contact Us
Make Great Medicine. 
And Then Do It Again 
and Again.
Science As Limitless 
As Our Curiosity
Humbled By 
Possibility
Make Great Medicine. 
And Then Do It Again 
and Again.
Science As Limitless 
As Our Curiosity
Humbled By 
Possibility
NOW APPROVED 
IN THE
UNITED STATES
Learn more
NEW INDICATION NOW APPROVED 
IN THE
UNITED STATES
Learn more
REGENERON NEWSROOM
Follow us
Our 2017 annual materials are now available, including our first consolidated Responsibility Report!
Read our 
annual report
 and 
responsibility report
 here
      GROWING UP, I WANTED
    TO BE A SCIENTIST,
  LAB COAT AND ALL
Visit our careers page
REGENERON PERSPECTIVES
An ongoing series of thought-provoking articles on issues of the day from Regeneron’s leaders.
The Latest
Making a Drug You Hope No One Will Ever Need
By: Neil Stahl, PhD
Executive Vice President, Research and Development
When the Student is a Computer: Teaching Machines to do New Tricks
By: Jeffrey Reid, PhD
Executive Director, Head of Genome Informatics
"For nearly 30 years, our mission has been to use the power of science to bring new medicines to patients... over and over again."
See our history
LEARN HOW WE ARE REVOLUTIONIZING A NOTORIOUSLY DIFFICULT DRUG DEVELOPMENT PROCESS
THE ROAD TO SEQUENCING OVER 500,000 PEOPLE STARTS HERE
OUR PIPELINE INCLUDES
OVER A DOZEN
HOMEGROWN ANTIBODIES
WE DO TAKE YOUR KID TO WORK DAY DIFFERENTLY
FROM THE VILLAGES OF SWAZILAND TO REGENERON LABS
Meet Innocent
MEET LEN & GEORGE
PROUD TO PRESENT
OUR COMMITMENT TO PATIENTS EXTENDS WELL BEYOND OUR LABS
Learn about our support programs
EXPLORE OUR PUBLICATIONS LIBRARY
MEET JEAN
When I was a little girl, I really  wanted to design princess dresses.
AS WE GROW, WE ARE MINDFUL OF OUR ENVIRONMENTAL FOOTPRINT
About
Leadership
History
Collaborations
Industrial Operations
Locations
Science
Pipeline
Research Areas
Technology
Regeneron Genetics Center
Scientific Publications
Medicines
ARCALYST® (rilonacept) INJECTION
DUPIXENT® (dupilumab) INJECTION
EYLEA® (aflibercept) INJECTION
KEVZARA® (sarilumab) INJECTION
LIBTAYO® (cemiplimab-rwlc) INJECTION
PRALUENT® (alirocumab) INJECTION
Citizenship
Science Education
Science Talent Search
Sustainable Communities
Supporting Patients
Culture of Integrity
Grants
Investors & Media
News
 Events & Presentations
Stock Information
Financial Information
Corporate Governance
FAQs
Careers
Scientists
Patients
Medical Professionals
Contact Us
Terms of Use
Privacy Policy
Social Media Terms of Engagement
Ireland Site
Contact Us
CAREERS
Join our team and help turn science into life-changing medicine.
Column 1
Investors & Media
News
Events & Presentations
Stock Information
Financial Information
Corporate Governance
FAQs
Patients
Medical Professionals
Scientists
Column 2
About Us
Leadership
History
Collaborations
Industrial Operations
Locations
Science
Pipeline
Research Areas
Technology
Regeneron Genetics Center
Scientific Publications
Column 3
Medicines
ARCALYST® (rilonacept) Injection
DUPIXENT® (dupilumab) Injection
EYLEA® (aflibercept) Injection
KEVZARA® (sarilumab) Injection
LIBTAYO® (cemiplimab-rwlc) Injection
PRALUENT® (alirocumab) Injection
Citizenship
Science Education
The Regeneron Science Talent Search
Sustainable Communities
Supporting Patients
Culture of Integrity
Grants
The site you are about to visit is maintained by a third party who is solely responsible for its content. We encourage you to read the privacy policy of every website you visit.
CANCEL
CONTINUE
TO VISIT ANOTHER REGENERON 
PHARMACEUTICALS WEBSITE.
CANCEL
CONTINUE
CONFIRMED!
Thank you for reaching out to us. We'll be in touch soon.
Regeneron Sites
") use "cookies". Cookies are small text files which are automatically placed on your computer by the internet browser when you visit the Sites. A cookie can, amongst other things, track the web pages you visit and the options you use. Regeneron Pharmaceuticals, Inc. and its affiliates, Regeneron Ireland Unlimited Company and Regeneron UK Limited (together, "
Regeneron
", "
we
", "
us
" or "
our
") use this data to make the Sites more user-friendly and efficient. We use Google Analytics cookie service to track and obtain reports on how visitors are using the Sites. The information obtained with this cookie, which includes the IP address of your computer, will be transmitted to and stored by Google on servers in the United States. Google may share that information with third parties if Google is obliged to do so by law or to the extent such third parties are processing this information on behalf of Google. Regeneron has no influence on such use.
Yes, I accept cookies